DDR1 and cancer: While our study primarily focuses on DDR1-high expressing NSCLC and TP53 mutant DLBCL, DDR1 expression is significantly elevated in 17 other cancer types, suggesting that NSC632839 holds potential as a therapeutic strategy for a broader range of DDR1-associated cancers.